Nine Diagnostics is a biotechnology company developing what it describes as “AI-enabled nanosensor technology” for functional precision medicine. According to the website, the company’s platform is designed to determine treatment effectiveness and discover new biology by analyzing molecular patterns from blood samples, with potential applications in oncology and drug development. In June 2026, the company announced it has been selected for the Damon Runyon Cancer Research Foundation’s InVEST Program, which the foundation describes as providing “a $50,000 investment to support any new company started by Damon Runyon alumni or current Clinical Investigators or Rachleff-Innovators.” Visit the #WebsiteWednesday link in our bio to learn more. #HealthTech #AI #WW